[Comment] Oral small-molecule GLP-1 receptor agonist for type 2 diabetes and obesity

00:00 - 20 Dec 2025

With the rising use of nutrient-stimulating hormone-based therapy for the treatment of obesity, developing oral alternatives could help address the limitations of injectable therapies, including needle phobia, injection site reaction, and storage concerns, and could ultimately improve patient acceptability. Peptide-based oral GLP-1 receptor agonists, such as oral semaglutide, are limited by the need for diet restriction, timing of administration, and low oral bioavailability.1 Peptide-based GLP-1 receptor agonists are also more costly to manufacture and require refrigeration.